Assessment of advanced glycation end-products as a biomarker of diabetic outcomes
Endocrinología, Diabetes y Nutrición · 2018-11 · 65 (9) · 540-545
DOI: 10.1016/j.endinu.2018.06.003 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Endocrinología, Diabetes y Nutrición, 2018-11. Verfasst von Olga Simó-Servat und 4 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfe…. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: European Foundation for the Study of Diabetes, Instituto de Salud Carlos III.
Abstract (Originalsprache)
There are substantial differences in the onset and severity of diabetes complications that are not fully explained by HbA1c levels and other risk factors. HbA1c is the gold standard for assessing metabolic control, but has limited value to identify patients at risk of developing diabetic complications. The main disadvantage of HbA1c is that it does not provide information about glycemic variability and does not reflect long-term exposure to hyperglycemia. One of the main pathogenetic mechanisms of diabetic complications is the generation and accumulation of advanced glycation end-products (AGEs). Based on its fluorescence properties, AGEs may be measured in tissues such as the skin or lens. These non-invasive measurements of AGE accumulation may be considered as promising biomarkers of late diabetic complications, and our objective is to summarize the available evidence supporting this statement. However, further translational research and prospective clinical trials are needed before these new biomarkers may be incorporated into clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain. Electronic address:…
- Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute Barcelona, Spain.
- Diabetes and Metabolism Research Unit, Vall d'Hebron Research Institute Barcelona, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain.
Förderung
- European Foundation for the Study of Diabetes
- Instituto de Salud Carlos III
Zitieren
APA
Simó-Servat, O., Planas, A., Ciudin, A., Simó, R., & Hernández, C. (2018). Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. Endocrinología, Diabetes y Nutrición, 65(9), 540-545. https://doi.org/10.1016/j.endinu.2018.06.003
Vancouver
Simó-Servat O, Planas A, Ciudin A, Simó R, Hernández C. Assessment of advanced glycation end-products as a biomarker of diabetic outcomes. Endocrinología, Diabetes y Nutrición. 2018;65(9):540-545. doi:10.1016/j.endinu.2018.06.003
BibTeX
@article{SimServat2018,
author = {Simó-Servat, Olga and Planas, Alejandra and Ciudin, Andreea and Simó, Rafael and Hernández, Cristina},
title = {Assessment of advanced glycation end-products as a biomarker of diabetic outcomes},
journal = {Endocrinología, Diabetes y Nutrición},
year = {2018},
volume = {65},
number = {9},
pages = {540--545},
doi = {10.1016/j.endinu.2018.06.003}
}
EUVIMED